Systemic Treatment With the ROCK2 Inhibitor Belumosudil in Ocular Chronic Graft-Versus-Host Disease

This publication has 25 references indexed in Scilit:

• Successful use of belumosudil in a patient with chronic ocular GVHD: A case report
  Transplant Immunology, 2025
• Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease
  Ophthalmology Science, 2024
• Ocular graft-versus-host disease (oGVHD): From A to Z
  Survey of Ophthalmology, 2023
• Can Janus kinase inhibition improve ocular graft versus host disease?
  The Ocular Surface, 2023
• Mapping research trends of chronic ocular graft-versus-host disease from 2009 to 2020: a bibliometric analysis
  International Ophthalmology, 2022
• Comparable meibomian gland changes in patients with and without ocular graft-versus-host disease after hematopoietic stem cell transplantation
  The Ocular Surface, 2022
• Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
  New England Journal of Medicine, 2021
• Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report
  Transplantation and Cellular Therapy, 2015
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
  Transplantation and Cellular Therapy, 2015
• International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)
  Scientific Reports, 2013